Kuros Biosciences AG (ETR:YTSN)
Germany · Delayed Price · Currency is EUR 31.26
+1.14 (3.78%)
At close: Jul 15, 2025, 5:30 PM CET
Kuros Biosciences AG Company Description
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
It operates through two segments, Medical Devices and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing.
The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.
Kuros Biosciences AG
| Country | Switzerland |
| Founded | 2016 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 122 |
| CEO | Christopher Fair |
Contact Details
Address: Wagistrasse 25 Schlieren, 8952 Switzerland | |
| Phone | 41 44 733 4747 |
| Website | kurosbio.com |
Stock Details
| Ticker Symbol | YTSN |
| Exchange | Deutsche Börse Xetra |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christopher Fair | Chief Executive Officer |
| Daniel Geiger | Chief Financial Officer |
| Sjoerd Musters | Chief Operating Officer |